Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotech company whose news flow is closely tied to the progress of its DARPin-based oncology pipeline. The company regularly issues updates on its clinical trials, preclinical data presentations and strategic collaborations, giving investors and observers insight into how its programs are advancing through development.
News about Molecular Partners often highlights milestones for its Radio-DARPin platform, including MP0712, a 212Pb-based candidate targeting DLL3 in small cell lung cancer and other neuroendocrine cancers, and MP0726, which targets mesothelin in cancers with high unmet need. Press releases describe regulatory steps such as Investigational New Drug applications, initiation of Phase 1/2a studies, and early human imaging data from compassionate care programs, as well as the role of its collaboration with Orano Med in radiotherapeutics.
Another major source of updates is the companys multispecific T cell engager MP0533, in Phase 1/2a for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome/AML. Molecular Partners reports interim clinical data, dosing refinements and response patterns, particularly in patients with lower disease burden, through conference presentations and ad hoc announcements. News items also cover MP0317, a tumor-localized CD40 agonist in an investigator-initiated Phase 2 trial in cholangiocarcinoma, and preclinical Switch-DARPin programs that use logic-gated immune activation.
Corporate communications further include quarterly and half-year financial results, cash runway commentary, and management changes such as the appointment of a Chief Scientific Officer. For readers following MOLN stock, this news page provides a centralized view of regulatory disclosures, scientific conference presentations and pipeline progress updates related to Molecular Partners DARPin therapeutics.
Molecular Partners (NASDAQ: MOLN) reported Q1 2025 financial results and key milestones. The company maintains a strong cash position of CHF 131 million as of March 31, 2025, providing funding into 2027. Two significant developments include:
1. The expansion of their partnership with Orano Med from 4 to 10 programs for Radio-DARPin therapies, with MP0712 progressing toward IND filing and initial clinical data expected in 2025.
2. Positive progress in the MP0533 Phase 1/2a trial, with cohort 8 showing increased response rates and depth in AML treatment. The study protocol has been amended and cohort 9 enrollment has begun.
The company expects total operating expenses of CHF 55-65 million for 2025, with approximately CHF 7 million in non-cash costs.
Molecular Partners (NASDAQ: MOLN) presented three significant developments at AACR 2025:
- Positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer, with clinical development starting in 2025
- Initial preclinical data on a new mesothelin-targeting Radio-DARPin for solid tumors
- Preclinical proof-of-concept data for a logic-gated CD3 Switch-DARPin T cell engager
The MP0712 program showed high tumor uptake and favorable safety profiles in mouse models. The mesothelin-targeting Radio-DARPin demonstrated strong tumor accumulation while avoiding interference from shed mesothelin. The Switch-DARPin technology showed specific T cell activation in the presence of target cells and achieved tumor regression in mice without peripheral T cell activation.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) held its Annual General Meeting where shareholders approved all Board proposals by a wide majority. The company, which develops DARPin therapeutics, reported a significant net loss of CHF 50.6 million for 2024, increasing the total loss carried forward to CHF 199.4 million.
Shareholders approved the annual review, financial statements, and compensation report. All Board members were re-elected for one-year terms, with William Burns re-elected as Chairman and reappointed as chair of the Nomination and Compensation Committee. KPMG AG Zurich was re-elected as statutory auditors for 2025, and Anwaltskanzlei Keller AG was chosen as independent proxy until 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) has announced three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago.
The presentations will showcase:
- MP0712, a Radio-DARPin targeting DLL3 labeled with 212Pb for small cell lung cancer treatment, co-developed with Orano Med, entering First-in-Human studies in 2025
- Initial preclinical data on a second 212Pb-based Radio-DARPin targeting mesothelin (MSLN) in solid tumors, also co-developed with Orano Med
- Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation for solid tumors
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its upcoming Annual General Meeting for 2025. The meeting is scheduled for Wednesday, April 16, 2025, at 9:00 CET, with doors opening at 8:30 CET. The event will take place at JED Events in Schlieren, Switzerland.
Molecular Partners (MOLN) reported its Q4 2024 and full-year financial results, highlighting significant progress in its DARPin therapeutics pipeline. The company ended 2024 with CHF 149.4 million in cash and equivalents, expected to support operations into 2027.
Key developments include:
- Radio-DARPin MP0712 targeting DLL3 to enter first human trials in 2025
- Strategic partnership with Orano Med expanded to ten Radio-DARPin programs
- MP0533 Phase 1/2a clinical trial showing improved response rates
- Total revenues of CHF 5.0 million in 2024 (down from CHF 7.0 million in 2023)
- Net loss of CHF 54.0 million (improved from CHF 62.0 million in 2023)
- Operating expenses of CHF 66.2 million (reduced from CHF 68.1 million in 2023)
The company raised approximately $20 million in October 2024 from investors including HBM Partners, focusing on radiopharmaceutical pipeline development.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
